Access count of this item: 591

Files in This Item:
File Description SizeFormat 
56_481.pdf757.19 kBAdobe PDFView/Open
Title: 腎移植: Marginal 症例への対応 - 基礎研究からの今後の展望 (第58回日本泌尿器科学会中部総会(金沢))
Other Titles: Kidney Transplantation: How Shall We Deal with Marginal Cases ? - Future Prospects from Basic Research
Authors: 市丸, 直嗣  KAKEN_name
矢澤, 浩治  KAKEN_name
高原, 史郎  KAKEN_name
Author's alias: Ichimaru, Naotsugu
Yazawa, Koji
Takahara, Shiro
Keywords: Kidney transplantation
Hepatocyte growth factor
Carbamylated erythropoietin
Issue Date: Aug-2010
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 56
Issue: 8
Start page: 481
End page: 484
Abstract: The research performed at the Department of Urology Osaka University Graduate School of Medicine is overviewed. Renal ischemia-reperfusion (I/R) injury is inevitable in transplantation and is related to longterm graft function. MF-1, a bifunctional hepatocyte growth factor-macrophage stimulating protein chimera, was found to prevent apoptosis. In our study, MF-1 directly guarded cultured proximal tubular epithelial cells from hypoxia-induced necrosis and apoptosis in vitro, and MF-1 treatment ameliorated renal dysfunction by preventing apoptosis in rat I/R injury model. The erythropoietin molecule modified by carbamylation (CEPO) has been identified and was demonstrated to protect several organs without increasing the hemoglobin concentration. The therapeutic effect of CEPO was evaluated using an endothelial tube formation assay, and a rat ischemia-reperfusion injury model. CEPO treatment induced more capillarylike formation than EPO. CEPO-treated kidneys showed minimal tubular apoptosis with increased peritubular capillary endothelial cells. We identified a new therapeutic approach using CEPO to protect the kidney from ischemia-reperfusion injury by promoting angiogenesis.
Rights: 許諾条件により本文は2011-09-01に公開
PubMed ID: 20808071
Appears in Collections:Vol.56 No.8

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.